Fesoterodine

Fesoterodine
Space-filling model of the fesoterodine molecule
Clinical data
Trade names Toviaz
AHFS/Drugs.com Monograph
MedlinePlus a609021
License data
Pregnancy
category
  • US: C (Risk not ruled out)
    Routes of
    administration    		 Oral
    ATC code
    Legal status
    Legal status
    • In general: ℞ (Prescription only)
    Pharmacokinetic data
    Bioavailability 52% (active metabolite)
    Protein binding 50% (active metabolite)
    Metabolism Hepatic (CYP2D6- and 3A4-mediated)
    Elimination half-life 7–8 hours (active metabolite)
    Excretion Renal (70%) and fecal (7%)
    Identifiers
    CAS Number
    PubChem CID
    IUPHAR/BPS
    DrugBank
    ChemSpider
    UNII
    KEGG
    ChEMBL
    ECHA InfoCard 100.167.339 Edit this at Wikidata
    Chemical and physical data
    Formula C26H37NO3
    Molar mass 411.278 g/mol
    3D model (JSmol)
     ☒N☑Y (what is this?)  (verify)

    Fesoterodine (INN, used as the fumarate under the brand name Toviaz) is an antimuscarinic drug developed by Schwarz Pharma AG to treat overactive bladder syndrome (OAB).[1] It was approved by the European Medicines Agency in April 2007,[2] the US Food and Drug Administration on October 31, 2008 [3] and Health Canada on February 9, 2012.[4]

    Fesoterodine is a prodrug. It is broken down into its active metabolite, desfesoterodine, by plasma esterases.

    Efficacy

    Fesoterodine has the advantage of allowing more flexible dosage than other muscarinic antagonists.[5] Its tolerability and side effects are similar to other muscarinic antagonists and as a new drug seems unlikely to make great changes in practices of treatment for overactive bladder.[5]

    References

    1. ↑ "Fesoterodine, New Drug Candidate For Treatment For Overactive Bladder – Pfizer To Acquire Exclusive Worldwide Rights". Medical News Today. 17 April 2006.
    2. ↑ "Toviaz: European Public Assessment Report, Revision 3 - Published 02/06/08". European Medicines Agency. 2 June 2008. Archived from the original on 2008-04-01.
    3. ↑ "Pfizer's Toviaz (fesoterodine fumarate) Receives FDA Approval for the Treatment of Overactive Bladder" (Press release). Pfizer Inc. 2008-10-31. Retrieved 2008-11-06.
    4. ↑ Notice of Decision for TOVIAZ
    5. 1 2 Vella, M.; Cardozo, L. (2011). "Review of fesoterodine". Expert Opinion on Drug Safety. 10 (5): 805–808. doi:10.1517/14740338.2011.591377. PMID 21639817.
    This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.